Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

• Autoři: SCHJESVOLD Fredrik H; DIMOPOULOS Meletios-Athanasios; DELIMPASI Sosana; ROBAK Pawel; CORIU Daniel; LEGIEC Wojciech; POUR Luděk; SPICKA Ivan; MASSZI Tamas; DORONIN Vadim; MINARIK Jiri; SALOGUB Galina; ALEKSEEVA Yulia; LAZZARO Antonio; MAISNAR Vladimir; MIKALA Gabor; ROSINOL Laura; LIBERATI Anna Marina; SYMEONIDIS Argiris; MOODY Victoria; THURESSON Marcus; BYRNE Catriona; HARMENBERG Johan; BAKKER Nicolaas A; HAJEK Roman; MATEOS Maria-Victoria; RICHARDSON Paul G; SONNEVELD Pieter
• Rok publikování: 2022
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: LANCET HAEMATOLOGY
• Fakulta / Pracoviště MU: Lékařská fakulta
• www: https://www.sciencedirect.com/science/article/pii/S2352302621003811?via%3Dihub
• Doi: http://dx.doi.org/10.1016/S2352-3026(21)00381-1
• Klíčová slova: Published Online; See Comment page e82; Malignancies; University of; Department of Hematology